What was Amgen's revenue performance in the first quarter of 2017?

Amgen reported total revenues of $5.46 billion for the first quarter of 2017, a slight decrease of 1% compared to $5.53 billion in the same period of 2016. Product sales were $5.20 billion, down 1% from $5.24 billion in the prior year, while other revenues decreased by 8% to $265 million.

How did Amgen's profitability change in the first quarter of 2017?

Profitability improved significantly. Net income rose by 9% to $2.07 billion in the first quarter of 2017, up from $1.90 billion in the same period of 2016. Diluted earnings per share increased by 12% to $2.79, compared to $2.50 in the prior year, driven by higher operating income and effective cost management.

What were the key drivers of the change in operating expenses?

Operating expenses decreased by 8% to $2.87 billion in the first quarter of 2017, down from $3.13 billion in the prior year. This reduction was attributed to ongoing transformation and process improvement efforts across the company, including lower R&D and SG&A expenses, and a favorable impact from the expiration of Enbrel® residual royalty payments.

Are there any significant legal or tax matters that investors should be aware of?

Amgen is involved in ongoing patent litigations related to its key products such as Sensipar® and Kyprolis®. Additionally, the company received Notices of Proposed Adjustment from the IRS for the years 2010-2012 concerning profit allocation between its U.S. and Puerto Rico entities. While Amgen disagrees with these proposed adjustments and plans to appeal, a final resolution could materially impact its results of operations and cash flows. The company also notes the ongoing discussion and potential changes to U.S. tax legislation.

AMGN 10-Q Quarterly Report Q1 FY2017 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported its first-quarter 2017 financial results, showcasing solid performance with a net income of $2.07 billion, or $2.79 per diluted share, a notable increase from the prior year. Total revenues slightly declined by 1% to $5.46 billion, primarily due to a decrease in other revenues, while product sales remained largely stable. The company demonstrated effective cost management, with operating expenses down 8% year-over-year, leading to an 8% increase in operating income. Key product sales showed mixed performance, with strong growth in Prolia® (21%) and Sensipar®/Mimpara® (15%), while Enbrel® experienced a significant decline (15%) due to competition. The company continued to return capital to shareholders through dividends and stock repurchases. Amgen also highlighted significant progress in its pipeline and regulatory submissions, including an expanded indication for XGEVA® and positive cardiovascular outcomes data for Repatha®.

Financial Highlights

55 data points

Beta

Revenue

$5.46B

0.8% Gross Margin

Net Income

$2.07B

0.4% Net Margin

EPS (Diluted)

$2.79

Total Assets

$77.86B

Cash & Equivalents

$3.36B

Free Cash Flow

$2.22B

Financial Statements

Beta

Revenue	$5.46B
Cost of Revenue	$996.00M
Gross Profit	$4.20B
SG&A Expenses	$1.06B
Operating Expenses	$2.87B
Operating Income	$2.59B
Interest Expense	$326.00M
Net Income	$2.07B
EPS (Basic)	$2.81
EPS (Diluted)	$2.79
Shares Outstanding (Basic)	737.00M
Shares Outstanding (Diluted)	741.00M

Key Highlights

1Net income increased by 9% to $2.07 billion, and diluted EPS grew by 12% to $2.79, indicating improved profitability.
2Total revenues saw a slight decrease of 1% to $5.46 billion, with product sales largely stable at $5.20 billion.
3Operating expenses decreased by 8% to $2.87 billion, contributing to an 8% increase in operating income, reflecting successful cost management and transformation efforts.
4Strong performance from key products like Prolia® (+21% sales) and Sensipar®/Mimpara® (+15% sales) offset declines in others.
5Enbrel® sales decreased by 15%, primarily attributed to increased competition.
6The company maintained a strong liquidity position with $38.4 billion in cash, cash equivalents, and marketable securities.
7Amgen announced positive clinical trial results for Repatha® regarding cardiovascular event reduction and expanded regulatory submissions for XGEVA®.

AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2017

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions